Skip to main content
. 2017 Oct 31;58(1):60–67. doi: 10.1007/s12088-017-0687-8

Table 2.

Antibiotic susceptibility profile of Vibrio fluvialis BD146 and its transconjugants

Vibrio fluvialis BD146 Transconjugants TRI20 + TET120 Transconjugants AMP50 + TET120 E. coli XL1-Blue
Resistant AMP, COT, CIP, SUL, NAL, TRI, RIF, CHL,GEN, STR, NOR, KAN, NEO, TET AMP, TET, TRI, RIF, NAL AMP, TET, RIF, NAL TET, NAL

Intermediate resistance and complete resistance were together considered as a resistance trait

AMP, Ampicillin (10 μg); CHL, Chloramphenicol (30 μg); CIP, Ciprofloxacin (5 μg); COT, Co-Trimoxazole (1.25 μg trimethoprim/23.75 μg sulfamethoxazole); GEN, Gentamicin (10 μg); KAN, Kanamycin (30 μg); NAL, Nalidixic Acid (30 μg); NEO, Neomycin (30 μg); NOR, Norfloxacin (10 μg); STR, Streptomycin (10 μg); SUL, Sulfisoxazole (300 μg); TET, Tetracycline (30 μg); TRI, Trimethoprim (5 μg); RIF, Rifampicin (5 μg)

TRI20, Trimethoprim (20 µg mL−1); TET120, Tetracycline (120 µg mL−1); AMP50, Ampicillin (50 µg mL−1)

Experiments were performed at least three times